AbCellera Biologics (ABCL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Antibody Discoverysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 11.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.7% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus
- AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
- AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
- AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
- Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
- AbCellera (ABCL) Q2 2026 Earnings Call Transcript
- AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?
- AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design, rationale, and methods. — Front Allergy 2025 PMID 41488220
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for AbCellera Biologics.
Full ABCL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.